Jun 6, 2024, 00:54
Discussing the practice changing LAURA trial – Two Onc Docs
Two Onc Docs shared a post on X/Twitter:
”Discussing the practice changing LAURA trial for stage 3 unresectable NSCLC for patients with EGFRm with the expert himself Suresh S. Ramalingam including:
- Why placebo control.
- Expected OS.
- Why indefinite treatment.
- Role for other driver mutations.”
Source: Two Onc Docs/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 14, 2024, 00:19
Nov 14, 2024, 00:02
Nov 13, 2024, 23:57
Nov 13, 2024, 23:54
Nov 13, 2024, 23:48
Nov 13, 2024, 23:46